CJC-1295 (No DAC) 15mg — Vial Spec, Reconstitution Math & COA

15mg Vial Specifications and High-Throughput Laboratory Overview

A 15mg mass specification of CJC-1295 (No DAC), also recognized chemically as Modified GRF (1-29), represents a high-density lyophilized mass intended for extensive laboratory research programs. This format is typically selected by research institutions conducting multi-arm preclinical trials, high-density receptor binding studies, or long-term cell culture series where batch-to-batch consistency across multiple assay plates is paramount. By sourcing a single 15mg vial, laboratories can minimize inter-assay variability by maintaining a unified analytical standard across extensive testing phases.

CJC-1295 (No DAC) operates as a synthetic tetrasubstituted analog of endogenous growth hormone-releasing hormone (GHRH). In preclinical models, GHRH peptides bind directly to the GHRH receptor (GHRH-R) on pituitary somatotropes, activating adenylate cyclase and downstream cyclic AMP (cAMP) signaling cascades. Note that while PX1 Research specializes in high-purity research compounds, availability of specific unit masses varies; researchers looking for standardized options can inspect our main CJC-1295 (No DAC) product page or review our complete selection of all peptides for currently stocked vial configurations.

Reconstitution Mathematics for 15mg CJC-1295 (No DAC) Mass Formats

Accurate concentration calculations are vital when reconstituting a high-mass lyophilized cake such as a 15mg vial. Because 15mg equals 15,000 micrograms (mcg), the volume of diluent added directly controls the resulting solution's volumetric concentration. Researchers utilizing automated liquid handlers or micro-pipettors must standardise these calculations prior to reconstitution to ensure precise micro-dosing in experimental assays.

Below are standard concentration parameters based on typical laboratory diluent volumes (Bacteriostatic Water or Sterile 0.9% Sodium Chloride):

• 1.0 mL Diluent Volume: Reconstituting 15mg in 1.0 mL yields a final concentration of 15.0 mg/mL (15.0 mcg/µL). A 10 µL transfer delivers 150 mcg of active peptide.

• 2.0 mL Diluent Volume: Reconstituting 15mg in 2.0 mL yields a final concentration of 7.5 mg/mL (7.5 mcg/µL). A 10 µL transfer delivers 75 mcg of active peptide.

• 3.0 mL Diluent Volume: Reconstituting 15mg in 3.0 mL yields a final concentration of 5.0 mg/mL (5.0 mcg/µL). A 10 µL transfer delivers 50 mcg of active peptide.

• 5.0 mL Diluent Volume: Reconstituting 15mg in 5.0 mL yields a final concentration of 3.0 mg/mL (3.0 mcg/µL). A 10 µL transfer delivers 30 mcg of active peptide.

To rapidly model custom concentrations or mix ratios for complex assay designs, researchers are encouraged to utilize our interactive reconstitution calculator to eliminate mathematical variance during solution preparation.

Aliquot Management and Freeze-Thaw Degradation Prevention

High-mass peptide vials present distinct analytical challenges regarding solution stability. Repeatedly puncturing a single vial stopper over prolonged experimental timelines increases the risk of atmospheric exposure, bacterial contamination, and peptide degradation via enzymatic or hydrolytic pathways. GHRH analogs containing sensitive amino acid residues can undergo deamidation or oxidation when subjected to multiple freeze-thaw cycles.

To preserve chemical integrity following initial reconstitution of a 15mg vial, research protocols should enforce immediate sub-aliquoting. The primary solution should be divided into single-use micro-centrifuge tubes or cryogenic vials tailored to daily experimental volume requirements. These aliquots must be flash-frozen and stored at -20°C or -80°C. Once an aliquot is thawed for an assay, any unused liquid should be discarded rather than re-frozen, protecting the remaining inventory from thermodynamic stress and structural degradation.

Analytical Verification: Lot-Matched COAs and Purity Standards

High-density unit fills demand stringent quality control protocols to ensure that high peptide content does not compromise purity or introduce lyophilisate aggregates. PX1 Research subjects every production lot to rigorous third-party testing within ISO 17025 accredited facilities. Laboratory researchers can verify product specifications directly by accessing our dedicated COA portal.

Analytical verification for CJC-1295 (No DAC) includes High-Performance Liquid Chromatography (HPLC) to confirm chemical purity standards exceeding 99%, along with Mass Spectrometry (MS) to verify precise molecular weight (3288.7 Da). Furthermore, high-throughput animal and cell-culture applications require strict control over endotoxin levels. PX1 Research enforces rigorous Limulus Amebocyte Lysate (LAL) testing on all lots to confirm endotoxin levels remain well below standard preclinical safety thresholds.

Comparative Analysis: GHRH Analogs and Secretagogue Classes

In cellular secretagogue investigations, CJC-1295 (No DAC) is frequently evaluated alongside other synthetic peptides targeting the somatotropic axis. Understanding structural and operational differences between these compounds allows researchers to select the optimal reagent for specific tissue repair or hormone pathway experiments.

While CJC-1295 (No DAC) acts directly as a GHRH receptor agonist, compounds like Ipamorelin target the growth hormone secretagogue receptor (GHSR-1a) as ghrelin mimetics. When researchers investigate synergistic activation of growth hormone pathways, GHRH analogs are often paired in vitro with ghrelin receptor agonists like GHRP-6. Conversely, baseline secretagogues such as Sermorelin feature shorter biological half-lives and distinct receptor binding dynamics. Comparing these mechanisms within our broader growth hormone secretagogues library assists principal investigators in structuring multi-variable laboratory protocols.

Preclinical Mechanisms: Tissue Repair & Somatotropic Signaling

Preclinical studies indicate that GHRH analogs play a central role in modulating downstream physiological cascades relevant to tissue repair, cellular regeneration, and metabolic homeostasis. By binding GHRH receptors, CJC-1295 (No DAC) triggers the transcription and release of endogenous growth hormone in a pulsatile manner, which subsequently stimulates hepatic and peripheral synthesis of Insulin-like Growth Factor 1 (IGF-1).

In vitro data and animal models suggest that elevated local IGF-1 concentrations promote satellite cell activation in skeletal muscle tissue, accelerate collagen deposition in connective tissues, and enhance osteoblast proliferation. Because CJC-1295 (No DAC) lacks the Drug Affinity Complex (DAC) modification, it does not form covalent bonds with circulating serum albumin. This results in a shorter biological half-life relative to DAC-bound variants, making it a preferred tool for research models examining acute, physiological GHRH receptor kinetics without inducing persistent receptor desensitization.

Storage, Handling, and Laboratory Reagent Integrity Protocols

Maintaining optimal storage conditions is imperative to prevent peptide breakdown. In its original lyophilized state, CJC-1295 (No DAC) 15mg powder remains stable when stored in a dry, dark environment at -20°C for up to 24 months. Exposure to ambient heat, light, or moisture can induce peptide aggregation and reduce functional activity.

Upon reconstitution with sterile, preserved diluent (such as 0.9% Benzyl Alcohol Bacteriostatic Water), liquid solutions must be kept refrigerated at 2°C to 8°C and evaluated within 28 days. Avoid violent vortexing during dissolution; gentle swirling or passive standing is recommended to preserve delicate secondary peptide structures. Laboratories managing high-volume testing schedules can review options for bulk purchasing and facility stocking via our wholesale accounts portal.

Selecting the Optimal Mass Format: 2mg, 5mg, or 15mg Vials

Selecting the correct vial size depends on experimental scale, assay frequency, and available laboratory infrastructure. A 15mg mass specification is optimal for large-scale operations requiring consistent stock solutions across multi-week studies. However, smaller mass formats are often more suitable for small-scale assays or pilot studies.

For small pilot studies or short-duration receptor assays, 2mg or 5mg vials reduce the risk of solution degradation associated with prolonged liquid storage. Conversely, high-throughput laboratories utilizing automated liquid handlers benefit from the reduced vial-swapping and uniform baseline math provided by a single 15mg format. Principal investigators should balance immediate concentration needs against storage capabilities when selecting vial sizes from our comprehensive research hub.